Progressive neuroinflammation and deficits in motor function in a mouse model with an *Epg5* pathogenic variant of Vici syndrome

Bradley T. Thornton[1], Alexandra G. Hardinger[2], Laramie Pence[3], Priyanka Prem Kumar[1], Nikolas Connolly[4], Scott J. Weir[5,6], Jay L. Vivian[1,3,7,8]

[1]Division of Clinical Genetics, Department of Pediatrics, Children's Mercy Kansas City, Kansas City MO USA

[2]Bioengineering Graduate Program, University of Kansas, Lawrence KS USA

[3]Genetically Engineered Mouse Models Core, Children's Mercy Research Institute, Children's Mercy Kansas City, Kansas City MO USA

[4]Interdisciplinary Graduate Program in Biomedical Sciences, University of Kansas Medical Center, Kansas City, KS, USA

[5]Department of Pharmacology and Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA

[6]Institute for Advancing Medical Innovation, University of Kansas Medical Center, Kansas City, KS, USA

[7]University of Missouri-Kansas City School of Medicine, Kansas City MO USA

[8]Author for correspondence:

jvivian@cmh.edu

Abstract

Vici syndrome (VS) is a rare pediatric genetic disorder characterized by profound developmental delay, seizures, immune deficits, cardiomyopathy, and progressive motor dysfunction. This devastating condition is caused by pathogenic variants in the *EPG5* gene, which encodes a regulator of autophagy, leading to the accumulation of toxic intracellular material and widespread cellular dysfunction. There are no effective treatments for disorders associated with pathogenic variants of EPG5. The underlying mechanisms driving the progressive neurological decline in VS remain poorly understood. Previous studies using *Epg5* knockout models have demonstrated severe neurological phenotypes; however these models have not been characterized for molecular and cellular deficits within the central nervous system. We report the generation and analysis of novel genetically engineered mice with mutations in *Epg5*, including a strain harboring a truncating mutation that recapitulates a VS patient-derived pathogenic variant and a strain with an *Epg5* null allele. These novel *Epg5* mutant mouse models exhibited partial perinatal lethality. Neurological deficits of surviving were detectable by six weeks of age, which worsen over time. Histological analysis revealed widespread expansion of microglia and astrocytes throughout the CNS. Transcriptomic profiling of CNS tissue revealed robust neuroinflammatory signatures, sharing molecular profiles with disease-associated microglia observed in other models of neurological disease and injury. The analysis of these novel mouse models of Vici syndrome suggest a critical role for neuroglial activation in the pathogenesis of VS. These novel in vivo models will be an essential platform for preclinical evaluation of therapeutics that target autophagy-related neurodegeneration in congenital disorders of autophagy.

24 **Keywords:**

25 Vici syndrome

26 EPG5

27 Autophagy

28 Microglia

29 Astrocyte

30 Neurodegeneration

31 Congenital disorders of autophagy

32 Pathogenic variant

33 Parkinson's disease

Introduction

Vici syndrome (VS; OMIM 242840; also known as EPG5-Related Disorder) is a rare, autosomal recessive, childhood-onset multisystem disorder that primarily affects the central nervous system, cardiac function, and immune response, among other organ systems[1-3]. Clinical manifestations typically emerge within the first year of life and include failure to thrive, global developmental delay, immunodeficiency with recurrent infections[4], and cardiomyopathy. Neurological features include hypotonia, developmental delay[5], seizures, progressive motor decline, and structural brain abnormalities[1]. Affected children are typically nonverbal and unable to ambulate[5]. VS follows a relatively progressive course, with a median survival of approximately 42 months; however, a range of phenotypes is observed, suggesting a spectrum influenced by the associated pathogenic variants[6,7]. Mortality is commonly attributed to a combination of progressive cardiomyopathy, recurrent infections, and respiratory compromise due to neuromuscular decline. Neurological deterioration is a nearly universal hallmark of this disease and significantly impairs quality of life[2]. Currently, no disease-modifying therapies exist, and clinical management remains largely supportive and palliative. The rarity of VS, coupled with limited access to patient-derived samples[8,9], and the absence of well-characterized disease models, has hindered both mechanistic understanding and therapeutic development.

A definitive diagnosis of VS is established through genetic testing, which reveals pathogenic variants in the *EPG5* gene[10,11]. *EPG5* (Ectopic P-granules protein 5) encodes a critical regulator of autophagy, facilitating the fusion of autophagosomes with lysosomes[12]. Most pathogenic variants identified in VS are nonsense or frameshift mutations[10] resulting in loss of function, although some missense mutations have also been reported[6]. Patient-derived cells exhibit impaired autophagic flux, characterized by the accumulation of undegraded autophagic material due to defective *EPG5*-mediated vesicle fusion[13,14]. VS is now recognized as part of a broader group of rare disorders[15,16] termed congenital disorders of autophagy (CDAs). Deficits in autophagy may drive a range of neurological disorders and other diseases[17,18], suggesting

new avenues for treatment using targeted therapies that modulate autophagy. A recent study of rare familial forms of Parkinson's disease have identified pathogenic variants in EPG5[19], suggesting deficits in EPG5 may drive a spectrum of neurodegenerative diseases beyond VS.

Previous studies using *Epg5* knockout models have demonstrated severe neurological phenotypes[20]; however, the molecular and cellular mechanisms underlying the progressive motor deficits in VS remain poorly understood. Moreover, no existing mouse models that recapitulate patient-specific *EPG5* mutations have been reported. To address this gap, we generated and characterized two novel *Epg5* mutant mouse strains: one harboring a truncating *W860X* pathogenic variant identified in a patient (case report in preparation) and another carrying a newly developed null allele. Both models exhibit early-onset and progressive neurological phenotypes, with subtle but significant differences between alleles. Whole animal deficits in motor function were evident by six weeks of age and worsen over time. Transcriptomic analyses of brain and spinal cord tissue from these models revealed robust neuroinflammatory signatures, implicating glial activation, particularly of microglia and astrocytes, in disease progression. Notably, the molecular profiles observed in *Epg5*-deficient mice share features with disease-associated microglia[21] identified in models of neurodegenerative disorders such as Alzheimer's disease and amyotrophic lateral sclerosis, suggesting potential mechanistic overlap. These findings enhance our understanding of VS pathogenesis and provide candidate biomarkers for disease monitoring. Furthermore, these models establish a critical platform for preclinical evaluation of therapeutic strategies for this devastating disorder.

Materials and Methods

Animal use

The mice were generated and maintained on a C57BL/6J genetic background, and the mutant stocks were maintained as heterozygotes by backcrossing to vendor-derived animals (Jackson Laboratories, Bar Harbor ME). Homozygous mutant mice were closely monitored for animal welfare concerns related to neurological dysfunction and removed from the study via approved euthanasia methods if any effects on welfare were identified. The animals were housed in a specific pathogen-free vivarium operating as a barrier facility in single-use disposable mouse cages (Innovive, San Diego CA) with a 12-hour light/dark cycle and maintained at 22°C +/-1.0°C and 40%+/-5% humidity. Pregnant dams and preweaning pups were fed high-fat chow and water ad libitum, and postweaning aged mice were fed standard laboratory chow and water ad libitum.

Generation of mouse strains with *Epg5 W860X* and *Epg5* knockout alleles

The design and validation of the CRISPR reagents used for in vivo genome editing were performed as described[22]. To generate the *Epg5-W860X* allele, a CRISPR target site (CCCGAATCACAGCTATCTCT) was identified in exon 14 of the mouse *Epg5* locus. To generate the *Epg5*-KO allele, a CRISPR target site (CGGGCTCTCCTGCTCGCGAC) was identified at the 5' end of exon 2 of the mouse *Epg5* locus. CRISPR reagents were synthesized as crRNAs and annealed to universal tracrRNAs (Integrated DNA Technologies, Coralville IA). Prior to production, the activity of the CRISPR reagents was verified via embryo electroporation of the Cas9/crRNA/tracrRNA ribonucleoprotein (RNP) complex. The *Epg5*-W860X mutant mice were produced as described[22,23] via CRISPR-mediated genome editing and homology-directed repair. Single-stranded donor DNA was designed for each allele (Supplemental Table 1) and generated via DNA synthesis (Integrated DNA Technologies, Coralville IA). For *Epg5*-W860X, the donor

108 DNA incorporated a single nucleotide change, resulting in a premature stop codon in exon 2
109 flanked by 88 bp and 68 bp of *Epg5* homology for targeting via homology-directed repair. The
110 CRISPR RNP complexes were coinjected with donor DNA into C57BL/6J zygotes[24], which were
111 subsequently transferred to pseudopregnant females[23] for delivery. The resulting founders were
112 confirmed for correct targeting of the donor DNA via allele-specific PCR and sequencing
113 (Supplemental Table 1). To produce the *Epg5*-KO strain, the CRISPR reagents were
114 electroporated into C57BL/6J zygotes, which were subsequently transferred to pseudopregnant
115 females for delivery. The resulting founders were analyzed for deletions generated via
116 nonhomologous end-joining via PCR, and the nature of the resulting mutations was confirmed
117 by next-generation sequencing of PCR amplicons. One founder harboring a 22-nucleotide
118 deletion in exon 2 resulting in a frameshift mutation was expanded by breeding to generate wild-
119 type C57Bl/6J mice. Germline transmission of each desired targeted allele was confirmed in F1
120 generation pups via PCR and sequencing.
121
122 **Behavior analysis**
123 The analysis of motor coordination, endurance, and fatigue resistance was performed via the
124 rotarod test (Panlab, Barcelona, Spain). The mice were acclimated and housed in rooms with an
125 adjusted light–dark cycle to allow for testing during the active dark phase. Test subjects were
126 given two training days with the apparatus set at 4 rpm for 1 minute for three runs each training
127 day. One week after training, the mice were tested every two weeks with the apparatus set at a
128 ramp speed from 4–40 rpm over the course of 300 seconds. The mice were tested for three
129 trials per testing day with an intertrial interval of 10–15 minutes. Failure to initiate was defined as
130 a trial in which the animal was unable to remain on the rod for one full revolution at 4 rpm at the
131 beginning of a test. The latency to fall and speed at fall data from each trial were recorded via
132 SEDACOM 2.0 software (Panlab, Barcelona, Spain). Data visualization and statistical analysis

133 were performed via Prism software (GraphPad, Boston, MA). Statistical analysis of data from
134 wild-type and mutant mice at a given timepoint was performed via an unpaired t test.
135
136 **Protein analysis**
137 Spinal cord tissues from 6-month-old wild-type and mutant siblings of each of the *Epg5* mutant
138 strains were dissociated in RIPA buffer (Thermo Fisher, Waltham, MA.) with a TissueRuptor
139 homogenizer (Qiagen, Hilden, Germany.). The supernatant was collected, and a protease and
140 phosphatase inhibitor cocktail (Thermo Fisher, Waltham, MA) was added. The protein
141 concentration of the supernatant was quantified via a Pierce BCA assay (Thermo Fisher,
142 Waltham, MA) per the manufacturer's protocol. Protein samples were denatured in Laemmli
143 sample buffer (Bio-Rad Laboratories, Hercules, CA), and 20 µg of protein from each sample
144 was used for western blot analysis. Antibodies against LC3 (Cell Signaling Technology, Danvers,
145 MA) and a-Tubulin (Cell Signaling Technology, Danvers, MA) and secondary antibodies (LI-COR
146 Biosciences, Lincoln, NE) were used to detect each protein. Fluorescent imaging was
147 performed on the membrane via an Odyssey CLx Imager (LI-COR Biosciences, Lincoln, NE).
148 Each band was quantified via ImageStudioLite analysis software (LI-COR Biosciences, Lincoln,
149 NE).
150
151 **Purification of microglia**
152 Primary microglia were isolated from 7 month-old wild-type and homozygous Epg5 W860X
153 mutant mice. Mice were euthanized via exsanguination via cardiac perfusion with cold PBS
154 under isoflurane anesthesia, after which whole brain was isolated. Whole brains were
155 processed according to manufacturer's protocol using enzymatic digestion and dissociation
156 (Adult Brain Dissociation Kit, GentleMACS Dissociator, and Debris Removal Solution; Miltenyi
157 Biotec, Bergisch Gladbach, Germany). Subsequent magnetic separation of purified microglia
158 was performed using CD11b microbeads and separation columns (Miltenyi Biotec). The purified

159 microglia were lysed immediately in Qiazol (Qiagen, Hilden, Germany) for use in RNA
160 purification.
161
162 **RNA analysis**
163 Gene expression analyses were performed on purified RNA from tissues and from purified
164 microglia harvested from 6 to 7 month-old wild-type and homozygous mutants of the *Epg5*
165 strains. The tissues or cells were lysed via Qiazol/chloroform extraction, and the RNA was
166 purified via a Qiagen RNeasy column purification kit (Qiagen, Hilden, Germany) according to the
167 manufacturer's protocols. The extracted RNA (1 µg of total RNA for tissues, 180 ng from purified
168 microglia) was then either given to the institutional genomics core for RNA sequencing or was
169 converted into cDNA for quantitative PCR. The qPCRs were performed using TaqMan Gene
170 Expression Master Mix (Thermo Fisher, Waltham, MA) and the indicated probes (Supplemental
171 Table 2). The samples were analyzed via the ViiA 7 real-time PCR system (Applied Biosystems,
172 Waltham, MA) according to the manufacturer's protocols. For plotting, the expression data were
173 normalized to the data of the wild-type control siblings.
174
175 **RNA-Seq bioinformatics analysis**
176 Transcriptomic profiling via bulk RNA sequencing was performed on RNA from the cerebellum
177 and spinal cord of homozygous W860X mice or their wild-type control siblings. RNA sequencing
178 was performed with stranded total RNA with a RiboZero Gold library preparation kit (Illumina,
179 San Diego CA) per the manufacturer's protocols. The RNA sequences were processed for gene
180 expression quantification. Standard two-group differential expression analysis of a set of RNA-
181 seq samples processed with Kallisto[25]. Output files were processed with tximport[26] to collapse
182 transcript counts to gene counts via the transcript-to-gene mapping table. The mouse reference
183 genome GRCm39 was used in the analysis. To generate a volcano plot, the processed average
184 differential expression data from the RNA-seq data consisting of 13,991 genes in the cerebellum

185 and 25,527 genes in the spinal cord were inputted into Prism (GraphPad, Boston, MA). For
186 comparative differential gene expression analysis between tissues, genes that had a $\log_2$(fold
187 change) of +1/-1 and a false discovery rate (adj. p value) of less than 0.01 were used.
188 Overlapping DEGs between tissues were identified via Venny
189 (https://bioinfogp.cnb.csic.es/tools/venny/index.html). The overlapping genes were then input
190 into Ingenuity Pathway Analysis (Qiagen, Hilden, Germany) for pathway analysis and to
191 g:Profiler[27] for Gene Ontology (GO) analysis. Altered pathways and associated p values were
192 visualized via Prism (GraphPad, Boston, MA).
193
194 **Histology**
195 Tissues were collected and processed as previously described[28]. In brief, 6-month-old
196 mutant or control mice were placed under anesthesia (isoflurane) for transcardial perfusion with
197 4% paraformaldehyde in PBS. CNS tissues were then removed and fixed overnight. The tissues
198 were then washed two times in PBS prior to preparation for histology.
199 For immunohistochemistry, the tissues were dehydrated and embedded in paraffin. The
200 10 μm sections were rehydrated via citrate antigen retrieval buffer for use in staining to detect
201 GFAP (HRP/DAB IHC Detection Kit, Abcam, Cambridge, UK) per the manufacturer's protocol. A
202 colorimetric reaction was performed using DAB.
203 For immunofluorescence imaging, the tissues were frozen for cryosectioning as
204 described[29]. In brief, 20 μm sections were cut. Direct conjugated antibodies to detect GFAP or
205 IBA-1 were used to detect astrocytes and microglia, respectively, and costained with DAPI to
206 detect nuclei. The sections were mounted with a coverslip with Fluormount G mounting media
207 (Thermo Fisher). Immunofluorescence imaging was performed on a Zeiss Axio Observer 7
208 microscope (Zeiss, Oberkochen, Germany). For quantification, images of distinct regions of the
209 spinal cord were imported into the Imaris software package (Oxford Instruments, Oxfordshire
210 UK). For each fluorophore, an absolute intensity threshold value was adjusted via the histogram

211 and standardized for each image. A new surface was created to measure the total area of the
212 image. The summed value of the combined area from each surface was divided by the total
213 area to obtain the percentage value of positivity for each image.

214 **Results**

215 To develop mouse models that recapitulate a pathogenic *EPG5* variant associated with
216 Vici syndrome, a novel mouse strain was generated via CRISPR-mediated zygotic
217 mutagenesis[22-24] on an inbred C57Bl/6J genetic background (Table 1; Supplemental Table 1).
218 One strain was engineered to carry the *Epg5 W860X* mutation, which mirrors a recently
219 identified pathogenic variant in a child with severe Vici syndrome (manuscript in preparation).
220 For comparison, a knockout (*KO*) strain was also generated by introducing a 22 bp interstitial
221 deletion near the start of exon 2, resulting in a frameshift and predicted early truncation of
222 the EPG5 protein. Following generation and colony expansion, each strain was intercrossed to
223 produce homozygous mutant mice.

224 Genotypic analysis of offspring at postnatal day 14 (P14) revealed an
225 underrepresentation of homozygous mutants for both the *W860X* and *KO* alleles (Table 2). Chi-
226 square analysis indicated that this loss was due to a reduced number of surviving males ($p =$
227 0.043 for *KO*; $p = 0.035$ for *W860X*). A small number of deceased pups at P1 were found to be
228 homozygous mutants, suggesting perinatal lethality associated with these alleles.

229 Surviving homozygous mutants were monitored longitudinally postweaning. Mice
230 homozygous for either the *W860X* or *KO* mutation were generally smaller than their wild-type
231 littermates, although only *W860X* mutants consistently exhibited reduced body size throughout
232 life (Figure 1A, B; Supplemental Figure 1). All the homozygous mutants displayed marked motor
233 deficits, particularly in hindlimb coordination. Compared with age-matched controls, mutant mice
234 exhibited abnormal hindlimb posture, characterized by a splayed stance and inability to support
235 body weight (Figure 1C, D). A moderate ataxic phenotype was evident, with wobbly, halting, and
236 slow gaits (Supplemental Movie 1). Owing to progressive motor impairment, most of the mice
237 were removed from the study by 7 months of age for animal welfare reasons (Figure 1E). No
238 sex differences were observed in the severity of motor deficits.

239 To quantitatively assess motor function, rotarod testing was conducted longitudinally
240 beginning at 8 weeks of age. Compared with their control littermates, both *W860X* and *KO*
241 homozygous mutants presented significantly impaired performance (Figure 1F-I). By 12 weeks,
242 some mutants were unable to remain on the rotating cylinder, and by 14 weeks, all *W860X*
243 homozygous mutants and, by 16 weeks, all KO homozygous mutants were unable to initiate the
244 test. Both male and female mutants were equally affected. Owing to the severity of motor
245 impairment, mutants were unable to perform additional coordination tests, such as beam
246 walking. These findings of deficits in motor function were similar to previous analysis of other
247 *Epg5* mutant mouse models[20]. These studies indicate early-onset and progressive deficits in
248 survival, growth, and motor function in both *Epg5* mutant strains, with modest differences in
249 severity between the two mutant alleles analyzed.
250 Tissues from each mutant strain were collected for transcript and autophagy analyses.
251 Compared with those of wild-type controls, RNA extracted from the spinal cords of *W860X*
252 homozygous mice presented significantly lower *Epg5* transcript levels (Figure 2A). Although not
253 statistically significant, a similar trend was observed in the cerebellum (Figure 2B), suggesting
254 tissue-specific transcript instability, potentially due to nonsense-mediated decay. In contrast, the
255 transcript levels in the *KO* mice were not reduced. Western blot analysis of the LC3 protein
256 (microtubule-associated protein 1 light chain 3 alpha) was used to assess autophagy (Figure
257 2C,D; Supplemental Figure 2). Analysis of LC3 via western blotting distinguishes the
258 cytoplasmic form of LC3 (LC3-I) from the autophagosome-localized LC3 (LC3-II). LC3-II is
259 subject to autophagy-mediated degradation; thus the steady state levels of LC3-II allow for an
260 assessment of autophagy. The autophagosome-associated LC3-II was elevated in spinal cord
261 lysates from both mutant strains compared to tissues from wildtype controls, indicating that
262 autophagic flux was impaired with a resulting LC3-II accumulation.
263 To characterize the neurological phenotype further, bulk RNA sequencing was performed
264 on cerebellar and spinal cord tissues from 6-month-old *W860X* homozygous mice and control

265 littermates. These CNS tissues were selected because of their roles in motor control. The
266 transcriptomic profiles (n=4 of each genotype, split evenly by sex) were consistent between the
267 sexes and were combined for this analysis. A substantial number of differentially expressed
268 genes (DEGs) were identified, with more genes upregulated than downregulated (Figure 3A, B).
269 Notably, genes associated with glial activation, including microglial markers (*Gpnmb*, *Itgax*) and
270 the astrocytic marker *Gfap* were upregulated, suggestive of a gliosis in these tissues. Several
271 Toll-like receptor genes (*Tlr2*, *Tlr7*), key components of innate immune signaling, were also
272 upregulated. Among the downregulated genes, *Myoc* (Myocilin) was nearly absent in the spinal
273 cord of *W860X* mutants but unchanged in the cerebellum. This gene is specifically expressed in
274 the *glia limitans superficialis*, a specialized astrocyte population localized to the thin surface
275 layer throughout the CNS.

276 Although distinct sets of DEGs were identified in the cerebellum and spinal cord
277 of *Epg5 W860X* mutants, a shared gene expression signature was also observed across both
278 tissues (Figure 3C; Supplemental Table 3). Analysis of these overlapping DEGs highlighted key
279 cellular pathways affected by the *W860X* mutation in CNS tissues (Figure 3D,E). Gene ontology
280 and pathway enrichment analyses confirmed that these shared DEGs were significantly
281 associated with inflammatory and immune responses. Pathways identified in this analysis
282 include cytokine, interferon, and complement inflammatory pathways. Cellular pathways
283 identified as neutrophil degranulation and phagosome formation may suggest components of a
284 microglial activation. Although several pathways were identified with pathogen response, this
285 analysis likely does not represent an inflammatory or cellular response to microbial insult, given
286 the specific pathogen-free status of the vivarium within which these animals were housed.
287 Collectively, these transcriptomic data define a novel and complex neuroinflammatory and glial
288 activation signature in mice carrying the *Epg5 W860X* pathogenic variant that is reminiscent of
289 other neurological disease or damage models involving neuroglia.

290 Previous studies have identified distinct molecular signatures associated with microglial
291 responses to neurological injury in various mouse disease models[21] and in human
292 neurodegenerative disorders[30]. Among these, a disease-associated microglia (DAM) signature,
293 also referred to as the neurodegenerative microglial phenotype (MGnD), has been
294 characterized by the upregulation of genes such as *Clec7a*, *Cst7*, and *Trem2*[21]. Transcriptomic
295 analysis of CNS tissues from *Epg5 W860X* homozygous mutant mice revealed upregulation of
296 many DAM-associated genes (Figure 3F), suggesting a glial response reminiscent of other CNS
297 injury models. To confirm that the increased expression of DAM markers observed in the bulk
298 transcriptomic data is due to upregulated expression in the microglia, microglia were purified
299 from dissociated whole brain from W860X homozygous mice or control wildtype siblings at 7
300 months of age using CD11b magnetic microbeads. Quantitative PCR (qPCR) analysis of gene
301 expression of DAM markers *Clec7a*, *Cst7*, *Itgax, and Ccl4* (Figure 3G,H) and other markers
302 indicative of an activated microglial state in neurological disorders[31-33] such as *Lilrb4a* and *Irf7*
303 (Figure 3H) were observed to be higher in the purified mutant microglia compared to control
304 when normalized for equal cell number. This important result confirms that the microglia in the
305 *Epg5* mutant mice display upregulated expression of these markers, indicative of a DAM
306 phenotype.
307 To further evaluate the expression of selected DEGs, RNA was isolated from the CNS
308 tissues of 7-month-old mutant and control mice for quantitative PCR (qPCR) analysis (Figure 4).
309 Genes were selected on the basis of the transcriptomic findings, with a focus on glial markers
310 (astrocytic and microglial), inflammatory mediators, interferon response genes, and other
311 relevant targets. All DEGs identified in the *W860X* model were also dysregulated in
312 the *Epg5 KO* mice, although with varying magnitudes (Figure 4A–D; Supplemental Figure 3,4).
313 For example, *Gpnmb* and *Gfap* expression was more severely elevated in *W860X* mutants than
314 in *KO* mice, whereas other genes presented similar expression levels across both models.
315 Notably, the severity of gene expression changes varied by tissue. *Tlr7* expression, for example,

316 was more severely affected in the cerebellum of *W860X* mutants, whereas spinal cord
317 expression levels did not differ significantly between the two models. These molecular findings
318 parallel the phenotypic severity observed in vivo, with similar levels of severity between the
319 mutant alleles, with the *W860X* mutants exhibiting somewhat more pronounced deficits than *KO*
320 mice.

321 To assess the temporal progression of the gene expression deficits associated with the
322 *Epg5* mutations, the expression of a subset of glial-specific genes was evaluated in 2- and 6-
323 month-old *W860X* and *KO* mutant mice compared with wild-type controls (Figure 5;
324 Supplemental Figure 5). The selected genes included the astrocyte marker *Gfap* and the
325 microglial markers *Gpnmb* and *Itgax*. Many of these genes were already significantly
326 upregulated at 2 months of age, particularly in the spinal cord of both mutant models (Figure
327 5A–D), and their expression increased further by 6 months. In contrast, the changes in gene
328 expression in the cerebellum of the *KO* mice were relatively modest at 2 months but became
329 more pronounced with age. Gene expression defects in additional cell subtypes were confirmed
330 in this analysis. *Tnc*, which encodes Tenascin C, a factor specifically expressed in the
331 Bergmann glia of the cerebellum[34], was substantially reduced at 6 months of age in both *Epg5*
332 mutant mouse models. *Aqp4*, which encodes aquaporin 4, a marker of a subtype of
333 perivascular-associated astrocytes[35], was significantly increased 3.3-fold in the *W860X*
334 homozygous mutant cerebellum in the RNASeq analysis. These results indicate that glial
335 phenotypes in *Epg5 W860X* mutants were already apparent at early adulthood stages and
336 progress with age, which is consistent with the age of observed deficits in motor function.

337 Given the strong glial signature observed via transcriptomic and qPCR analyses,
338 histological studies were performed to assess astrocyte and microglial distribution and
339 phenotype in CNS tissues from 7-month-old *Epg5 W860X* mutants and control wildtype
340 littermates. Immunohistochemistry revealed a substantial increase in GFAP-positive astrocytes
341 across all CNS regions examined, which was consistent with elevated *Gfap* transcript levels

342 (Figure 6A, B; Figure 7A–D). Immunofluorescence staining for GFAP and the microglial marker
343 IBA1 confirmed widespread astrocyte and microglial expansion in the spinal cord (Figure 6C–N)
344 and cerebellum (Figure 7E–G) in *Epg5* mutant mice. Microglia exhibited a hypertrophic, spider-
345 like morphology with extended processes (Figure 6G, arrowhead), indicative of activation. In the
346 cerebellum, increased numbers of astrocytes and microglia were observed across multiple
347 layers, including the molecular layer (ML), internal granule layer (IGL), and white matter (WM)
348 (Figure 7F, G). Despite these cellular changes, the overall cerebellar architecture remained
349 intact.
350 While glial expansion was broadly distributed, certain white matter regions presented
351 particularly dense microglia and astrocyte accumulation. In the spinal cord, microglia were
352 notably concentrated in the dorsal funiculus (Figure 6I–K), a region containing descending
353 corticospinal and ascending sensory tracts. Additionally, both astrocytes and microglia were
354 enriched along the surface of the spinal cord (Figure 6C, D, L–N). While astrocytes are normally
355 present in this region, their numbers and process extension were markedly increased in mutants
356 (Figure 6D, M). Microglia, which are typically sparse at the surface, were also significantly
357 expanded (Figure 6M). These findings demonstrate a robust and progressive glial response in
358 the CNS of *Epg5 W860X* mutant mice, which is correlated with the observed motor deficits and
359 supports a role for glial dysfunction in the pathogenesis of Vici syndrome.
360

361 **Discussion**

362 The complex etiology of Vici syndrome (VS) remains incompletely understood,
363 contributing to the current lack of effective therapeutic strategies. In particular, the molecular
364 and cellular basis for the neurological manifestations of VS, which are universally present in VS
365 individuals, remain poorly characterized. This study presents the first published analysis of a
366 novel mouse model harboring a pathogenic variant in *Epg5* that mirrors a mutation identified in
367 VS patients. Specifically, the *Epg5-W860X* allele recapitulates the *EPG5-W865X* nonsense
368 mutation found in a clinically severe VS patient (manuscript in preparation). Homozygous
369 *W860X* mutant mice exhibit profound motor deficits that are comparable in severity to those
370 observed in both the *Epg5* knockout (*KO*) mice analyzed in this study and the previously
371 reported *Epg5*-deficient models[20].

372 Focusing on the molecular and cellular underpinnings of neurological dysfunction, our
373 analysis revealed previously unreported CNS phenotypes in these models. Using established
374 molecular markers, we observed widespread and progressive expansion of astrocytes and
375 microglia throughout the CNS in *Epg5* mutant mice. This glial expansion increases with age and
376 correlates with the severity of motor dysfunction, with significant motor deficits and glial marker
377 upregulation evident by two months of age. Notably, a molecular signature of
378 neuroinflammation, characterized by astrocyte and microglial expansion, suggests a
379 contributory role for glial cells in VS pathogenesis and disease progression. Previous studies
380 using *Epg5* mutant mice revealed inflammatory and immune-related phenotypes[36,37], including
381 gastrointestinal and peripheral immune dysfunction. In conjunction with these prior studies, the
382 findings in this study suggest the presence of an inflammatory phenotype across multiple organ
383 systems in *Epg5*-mutant mice, underscoring the potential for inflammation contributing to the
384 multisystemic nature of the disease. Specific CNS molecular markers may thus serve as
385 indicators of disease progression and severity.

386 Comparative analysis of the mutant alleles confirmed that the *W860X* and *KO* alleles
387 presented severe loss-of-function mutations. This aligns with the clinical severity observed in
388 the patient harboring the corresponding *W865X* mutation, who succumbed to the disease at 16
389 months of age (clinical report in preparation). The reduced *Epg5* transcript levels in *W860X*
390 mutant mice suggest that the mRNA is subject to nonsense-mediated decay. Owing to the lack
391 of a high-quality antibody for mouse EPG5, protein levels associated with the mutations
392 generated in this report could not be assessed via western blot. However, unpublished data
393 from patient-derived cells from our lab indicate that the *W860X* pathogenic variant does not
394 produce a stable truncated protein, further supporting its classification as a null allele.
395 A novel and striking observation in our study was the reduced survival of male mice
396 homozygous for either the *W860X* or *KO* allele, an outcome not previously reported in other
397 *Epg5* mutant models. This discrepancy may reflect differences in experimental design, such as
398 the depth of analysis of progeny from heterozygous intercrosses or potential residual activity of
399 the allele used in earlier studies. In humans, VS is associated with early-onset hypotonia and
400 failure to thrive. The reduced perinatal survival of homozygous mutant mouse pups may mirror
401 this clinical phenotype. Further investigations are needed to elucidate the mechanisms
402 underlying the observed male-specific lethality. Interestingly, previous studies reported sex-
403 dependent differences in microglial abundance and activity during both embryonic development
404 and adulthood[38]. Future analyses of *Epg5* mutant tissues at late prenatal and early postnatal
405 stages will be critical for understanding the origins of this lethality and defining the earliest
406 manifestations of glial dysregulation associated with the defective autophagy in this model.
407 One of the most striking transcriptional changes observed in the spinal cord of *Epg5*
408 mutant mice was the downregulation of *myocilin (Myoc)*, a marker of a specialized astrocyte
409 subtype known as the *glia limitans superficialis* (GLS)[39]. GLS astrocytes are localized to the pial
410 surface of the brain and spinal cord and are thought to contribute to barrier function and immune
411 surveillance. *Myoc* expression is initiated postnatally in these cells, suggesting Myoc is a marker

412 for developmental maturation of GLS cells. The substantial downregulation of *Myoc* in *Epg5*
413 mutant mice implicates a requirement for autophagy, either directly or indirectly, in the survival
414 or maturation of GLS astrocytes. Interestingly, our histological analysis revealed an expansion
415 of astrocytes and microglia at the surface of the spinal cord, suggesting that reactive gliosis may
416 interfere with GLS maturation. Further studies are needed to determine whether this represents
417 a cell-autonomous defect in GLS astrocytes or a secondary effect of microglial activation and
418 inflammation. Understanding the role of GLS astrocytes in CNS homeostasis and their potential
419 involvement in VS pathogenesis could provide new insights into how autophagy deficits disrupt
420 glial development and function. Efffect on glial maturation, function, or survival associated with
421 loss of EPG5 function is likely to be highly cell subtype specific. For example, expression of
422 genes associated with astrocyte function such as *Kcnj10* or *Slc1a3*, which encodes Kir4.1
423 channel and EAAT1 respectively, with functions to clear extracellular potassium and
424 glutamate[40,41], were not seen to be disrupted in the transcriptomic datasets. Single cell analyses
425 methods will be important to assess these cell subtype-specific deficits in detail.
426 Previous reports on *Epg5* mutant mice using a null allele have demonstrated partial
427 phenotypic overlap with the disease presentations in Vici syndrome patients[20], though not all
428 hallmark features were recapitulated to the same level of severity[9]. VS patients exhibit variable
429 age of death[7,11] attributed to a combination of loss of cardiac function, progressive loss of motor
430 function, and immune system deficits. The analysis presented here of the newly developed
431 *Epg5* mutant mouse models have identified perinatal lethality in approximately half of the male
432 homozygotes, potentially modeling the perinatal failure-to-thrive phenotype observed in many
433 VS patients[2], possibly due to deficits in swallowing. While cardiac and immune deficits in these
434 new mouse models remain areas for future investigation, this study focuses on neurological
435 manifestations. Although VS patients typically present with more severe CNS involvement[11], our
436 mouse model exhibits a progressive neurodegenerative phenotype, which may be attenuated by
437 the controlled laboratory environment. Future studies incorporating different genetic

438 backgrounds or environmental stressors may unmask additional phenotypes in the mouse
439 models. Importantly, while cellular and molecular deficits in the CNS of VS patients remain
440 poorly defined, including a gliosis[11], our work significantly expands potential molecular and
441 cellular aspects of the disease. The neuroinflammatory signatures and glial expansion in the
442 mouse models suggest potential parallels in human pathology. Validation of these findings in
443 precious VS patient CNS samples[8] will be critical to confirm this translational relevance.

444 Astrocytes and microglia are essential for maintaining central nervous system
445 homeostasis and play increasingly recognized roles in modulating disease progression[42,43].
446 Astrocyte homeostatic functions[44,45] include synaptic maintenance, neurotransmitter recycling,
447 integrity of the blood–brain barrier, and metabolic support of neurons. Microglia, the resident
448 innate immune cells of the CNS, are responsible for the phagocytosis of cellular debris,
449 apoptotic cells, and pathogens[46]. These glial cells not only are passive support cells but are also
450 highly dynamic[47,48], responding to environmental cues and pathological states with complex
451 molecular and functional changes in a coordinated fashion[49]. In disease or injury contexts, glial
452 cells display a range of functional plasticity, which can adopt a range of activation states,
453 including proinflammatory and neuroprotective phenotypes[50]. Importantly, these cell types can
454 adopt complex molecular phenotypes[48,51] that may be either neuroprotective or neurotoxic
455 depending on the context and duration of activation. Both astrocytes and microglia can secrete
456 cytokines and chemokines depending on the activation state[52,53], which influences the local
457 microenvironment and contributes to neuroinflammatory cascades. Microglia play a critical role
458 in synaptic pruning during development and in response to injury[54].

459 There is growing appreciation for the dual roles of glial cells in contributing to the
460 pathogenesis of neurological disorders. Dysregulation of glial function has been implicated in a
461 wide range of neurodegenerative diseases[55-57], including Alzheimer's disease (AD), Parkinson's
462 disease (PD), and amyotrophic lateral sclerosis (ALS). In models of AD, PD, and ALS, microglial
463 activation has been shown to be correlated with disease progression. For

464 example, *APOE* alleles associated with increased AD risk have been linked to altered microglial
465 responses[58], whereas *SOD1* mutations in ALS models have demonstrated that glial dysfunction
466 can exacerbate motor neuron degeneration[59]. These findings underscore the importance of glial
467 cells not only as responders to neuronal injury but also as active participants in disease
468 mechanisms. A recent study reported the exciting observation of non-null alleles of *EPG5* as
469 pathogenic variants for rare early onset Parkinson's disease[19]. Future studies will be needed to
470 ascertain the extent of the glial deficits in the CNS of these patients, and the role in Parkinson's
471 disease progression.

472 Whole-transcriptome analysis of CNS tissues from *Epg5* mutant mice revealed a
473 signature of activated microglia resembling other mouse CNS injury or disease models[21,60]. This
474 distinct transcriptional profile, known as disease-associated microglia (DAM), also referred to as
475 the neurodegenerative microglial phenotype (MGnD), has been identified in multiple models of
476 neurodegeneration or injury. This phenotype is characterized by the upregulation of genes such
477 as *Apoe*, *Trem2*, and *Cst7*, which are not typically induced in classical inflammatory responses
478 such as lipopolysaccharide (LPS) exposure[21]. DAM microglia are thought to play complex roles
479 in disease progression, being initially protective via microglial phagocytic activity by clearing
480 debris, but there is evidence that they may contribute to disease progression if chronically
481 activated[61]. Future studies involving single cell analysis of microglia in the *Epg5* mutant mice will
482 be needed to uncover the spectrum of the microglial phenotypes in these mice and the regional
483 differences in microglial states within the CNS, and how these may change over the course of
484 the lifespan.

485 The complex neuroinflammatory signature seen in *Epg5* mutant mice suggest that glial
486 dysfunction may be a key driver of disease progression in Vici syndrome. The localized
487 accumulation of microglia in specific regions of the spinal cord in *Epg5* mutant mice, specifically
488 in white matter, may point to possible cellular mechanisms for a role of microglia in neuronal
489 function in this model. Notably, microglial localization to specific CNS regions, such as the

490 corticospinal tract in models of ALS[62], has been associated with region-specific vulnerability.
491 Whether spatial differences in glial activation in *Epg5* mutant mice or VS remains to be
492 determined. The neurological phenotypes observed in *Epg5* mutant mice likely arise from a
493 combination of neuronal and glial dysfunction driven by impaired autophagy. Future studies
494 using primary cell cultures from these mice, as well as human induced pluripotent stem cell
495 (iPSC) models derived from VS patients[63], will be essential for dissecting the cell type-specific
496 consequences associated with EPG5 loss. The development of new mouse and cellular models
497 that allow for tissue-specific manipulation of EPG5 function and autophagy will be critical for
498 determining the extent to which glial dysfunction contributes to disease progression in VS and
499 other congenital disorders of autophagy. Ultimately these models will be critical to determine
500 the molecular mechanisms that give rise to the complex cellular deficits seen in Vici syndrome.
501 These studies will have major implications into potential therapeutic targets.
502 In conclusion, this study presents a detailed analysis of novel mouse models of Vici
503 syndrome, including a strain harboring a pathogenic variant in *Epg5* that mirrors a mutation
504 identified in VS patients. Our transcriptomic analysis of CNS tissues revealed a complex
505 molecular signature of neuroinflammation. Widespread and progressive expansion of astrocytes
506 and microglia was observed throughout the CNS in these mutant mice, and this glial activation
507 correlated with age and the severity of motor dysfunction. The detailed analysis of these mouse
508 models suggests a contributory role for glial cells in the pathogenesis and disease progression
509 of Vici syndrome. These studies validate the utility of these mouse models for study the
510 progression of VS, and for use in therapeutic assessment for this devastating disorder, including
511 the potential for targeting neuroglia as therapeutic strategy.
512

Acknowledgments

The generation of the animal models was performed by the Genetically Engineered Mouse Models Core of Children's Mercy Research Institute and the Transgenic and Gene Targeting Institutional Facility of the University of Kansas Medical Center as Shared Resources of the University of Kansas Cancer Center (NIH P30 CA168524). We acknowledge the efforts of Jing Huang and Sarah E Tague in the Histology and Integrative Imaging of the Kansas Intellectual and Developmental Disabilities Resource Center at the University of Kansas Medical Center. We wish to acknowledge the efforts of cores of the Children's Mercy Research Institute, including RNA sequencing and analysis were performed by the Genomic Core Service Center of the Children's Mercy Research Institute, and tissue preparation and sectioning were performed by the Children's Mercy Pathology Core.

525 **Abbreviations**

526 EPG5: Ectopic P Granules 5

527 VS: Vici syndrome

528 AD: Alzheimer's disease

529 PD: Parkinson's disease

530 ALS: Amyotrophic lateral sclerosis

531 iPSC: induced pluripotent stem cell

532 CNS: central nervous system

533 GLS: glia limitans superficialis

534 DAM: Disease-associated microglia

535 MGnD: neurodegenerative microglia

536 **Ethical research statement**

537 All animal procedures were approved by the Children's Mercy Research Institute Institutional
538 Animal Care and Use Committee. All housing, experimental procedures, and monitoring fully
539 conformed to ethical principals in the Guide for the Care and Use of Laboratory Animals, and all
540 euthanasia procedures conformed with the American Veterinary Medical Association's
541 guidelines for euthanasia.

542

543 **Data availability**

544 The RNA sequencing datasets supporting the conclusions of this study have been deposited in
545 the NCBI Gene Expression Omnibus (GEO accession numbers GSE307849). All other data can
546 be found within the article and its supplementary information.

547

548 **Competing interests**

549 The authors declare that they have no competing or financial interests.

550

551 **Funding**

552 This study was supported by Mercy Research Partners of Children's Mercy Kansas City, the Vici
553 Syndrome Foundation, and Vici syndrome families.

554

555 **Author contributions**

556 All the authors read and approved the final manuscript.

557 Conceptualization: JLV, SJW

558 Investigation: BTT, LP, AGH, PPK, NC, JLV

559 Data curation: BTT,LP, AGH,PPK,JLV

560 Formal analysis: LP, JLV

561 Writing – original draft: JLV

Writing – review and editing: BTT,LP, AGH,PPK,JLV

Visualization: BTT, AGH, and JLV

Funding acquisition: JLV

569 **Table 1.** Summary of mutant mouse strains
570

Mouse allele	*Epg5* exon	Mutation[1]	human pathogenic variant[2]	human gnomAD variant ID	human RefSNP ID
KO	2	p.R41QfsTer8 (c.122_143del)	n/a	n/a	n/a
W860X	14	p.W860X	W865X (c. 2595G>A)	SNV : 18-45925861 - C-T	rs1160786631

571
572 [1]mouse accession number: NM_001195633.2
573 [2]human accession number: NM_020964.3

Table 2. Summary of the genotypes of offspring from intercrosses of heterozygous *Epg5* mutant mice

		***Epg5* allele**					
		KO			***W860X***		
		Total	M	F	Total	M	F
genotype	expected	107	56	51	249	126	123
wt	25%	31.8%	32.1%	31.4%	30.1%	29.4%	30.9%
het	50%	55.1%	57.1%	52.9%	51.8%	55.6%	48.0%
mut	25%	13.1%	10.7%	15.7%	18.1%	15.1%	21.1%
p value		0.014	0.043	0.261	0.023	0.035	0.280
significance		*	*	NS	*	*	NS

Total: total number of mice analyzed from heterozygous intercrosses
M: number of male mice
F: number of female mice
*: $p<0.05$ according to the chi square test
NS: not significant

References

1. Dionisi Vici, C. *et al.* Agenesis of the corpus callosum, combined immunodeficiency, bilateral cataract, and hypopigmentation in two brothers. *Am J Med Genet* **29**, 1-8 (1988).
2. Byrne, S., Dionisi-Vici, C., Smith, L., Gautel, M. & Jungbluth, H. Vici syndrome: a review. *Orphanet J Rare Dis* **11**, 21 (2016).
3. Dafsari, H.S. *et al.* EPG5-Related Disorder. in *GeneReviews((R))* (eds. Adam, M.P. *et al.*) (Seattle (WA), 1993).
4. Finocchi, A. *et al.* Immunodeficiency in Vici syndrome: a heterogeneous phenotype. *Am J Med Genet A* **158A**, 434-9 (2012).
5. del Campo, M. *et al.* Albinism and agenesis of the corpus callosum with profound developmental delay: Vici syndrome, evidence for autosomal recessive inheritance. *Am J Med Genet* **85**, 479-85 (1999).
6. Kane, M.S. *et al.* Aberrant splicing induced by the most common EPG5 mutation in an individual with Vici syndrome. *Brain* **139**, e52 (2016).
7. Vansenne, F. *et al.* Phenotypic expansion of EGP5-related Vici syndrome: 15 Dutch patients carrying a founder variant. *Eur J Paediatr Neurol* **41**, 91-98 (2022).
8. Touraine, R. *et al.* Autopsy findings in EPG5-related Vici syndrome with antenatal onset. *Am J Med Genet A* **173**, 2522-2527 (2017).
9. Zhao, Y.G., Zhao, H., Sun, H. & Zhang, H. Role of Epg5 in selective neurodegeneration and Vici syndrome. *Autophagy* **9**, 1258-62 (2013).
10. Cullup, T. *et al.* Recessive mutations in EPG5 cause Vici syndrome, a multisystem disorder with defective autophagy. *Nat Genet* **45**, 83-7 (2013).
11. Byrne, S. *et al.* EPG5-related Vici syndrome: a paradigm of neurodevelopmental disorders with defective autophagy. *Brain* **139**, 765-81 (2016).
12. Wang, Z. *et al.* The Vici Syndrome Protein EPG5 Is a Rab7 Effector that Determines the Fusion Specificity of Autophagosomes with Late Endosomes/Lysosomes. *Mol Cell* **63**, 781-95 (2016).
13. Hori, I. *et al.* Defects in autophagosome-lysosome fusion underlie Vici syndrome, a neurodevelopmental disorder with multisystem involvement. *Sci Rep* **7**, 3552 (2017).
14. Piano Mortari, E. *et al.* The Vici syndrome protein EPG5 regulates intracellular nucleic acid trafficking linking autophagy to innate and adaptive immunity. *Autophagy* **14**, 22-37 (2018).
15. Ebrahimi-Fakhari, D. *et al.* Congenital disorders of autophagy: an emerging novel class of inborn errors of neuro-metabolism. *Brain* **139**, 317-37 (2016).
16. Dafsari, H.S. *et al.* An update on autophagy disorders. *J Inherit Metab Dis* **48**, e12798 (2025).
17. Stamatakou, E. *et al.* Mendelian neurodegenerative disease genes involved in autophagy. *Cell Discov* **6**, 24 (2020).
18. Klionsky, D.J. *et al.* Autophagy in major human diseases. *EMBO J* **40**, e108863 (2021).
19. Sun, Q.Y. *et al.* Biallelic Variants in EPG5 Gene Are Associated with Parkinson's Disease. *Ann Neurol* **98**, 369-385 (2025).
20. Zhao, H. *et al.* Mice deficient in Epg5 exhibit selective neuronal vulnerability to degeneration. *J Cell Biol* **200**, 731-41 (2013).
21. Barclay, K.M. *et al.* An inducible genetic tool to track and manipulate specific microglial states reveals their plasticity and roles in remyelination. *Immunity* **57**, 1394-1412 e8 (2024).
22. Larson, M.A., Gibson, K.A. & Vivian, J.L. In Vivo Validation of CRISPR Reagents in Preimplantation Mouse Embryos. *Methods Mol Biol* **2066**, 47-57 (2020).
23. Larson, M.A. Embryo Transfer Surgery. *Methods Mol Biol* **2066**, 101-106 (2020).

24. Larson, M.A. Pronuclear Microinjection of One-Cell Embryos. *Methods Mol Biol* **2066**, 27-33 (2020).
25. Bray, N.L., Pimentel, H., Melsted, P. & Pachter, L. Erratum: Near-optimal probabilistic RNA-seq quantification. *Nat Biotechnol* **34**, 888 (2016).
26. Soneson, C., Love, M.I. & Robinson, M.D. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. *F1000Res* **4**, 1521 (2015).
27. Kolberg, L. *et al.* g:Profiler-interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update). *Nucleic Acids Res* **51**, W207-W212 (2023).
28. Bhattacherjee, A. *et al.* Neuronal cytoskeletal gene dysregulation and mechanical hypersensitivity in a rat model of Rett syndrome. *Proc Natl Acad Sci U S A* **114**, E6952-E6961 (2017).
29. Yang, F.C. *et al.* Short Term Development and Fate of MGE-Like Neural Progenitor Cells in Jaundiced and Non-Jaundiced Rat Brain. *Cell Transplant* **27**, 654-665 (2018).
30. Keren-Shaul, H. *et al.* A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. *Cell* **169**, 1276-1290 e17 (2017).
31. Grubman, A. *et al.* Transcriptional signature in microglia associated with Abeta plaque phagocytosis. *Nat Commun* **12**, 3015 (2021).
32. Cohen, M. *et al.* Chronic exposure to TGFbeta1 regulates myeloid cell inflammatory response in an IRF7-dependent manner. *EMBO J* **33**, 2906-21 (2014).
33. Noh, M.Y. *et al.* Biomarkers and therapeutic strategies targeting microglia in neurodegenerative diseases: current status and future directions. *Mol Neurodegener* **20**, 82 (2025).
34. Yuasa, S. Bergmann glial development in the mouse cerebellum as revealed by tenascin expression. *Anat Embryol (Berl)* **194**, 223-34 (1996).
35. Amiry-Moghaddam, M. & Ottersen, O.P. The molecular basis of water transport in the brain. *Nat Rev Neurosci* **4**, 991-1001 (2003).
36. Lu, Q. *et al.* Homeostatic Control of Innate Lung Inflammation by Vici Syndrome Gene Epg5 and Additional Autophagy Genes Promotes Influenza Pathogenesis. *Cell Host Microbe* **19**, 102-13 (2016).
37. Lee, S. *et al.* Intestinal antiviral signaling is controlled by autophagy gene Epg5 independent of the microbiota. *Autophagy* **18**, 1062-1077 (2022).
38. Han, J., Fan, Y., Zhou, K., Blomgren, K. & Harris, R.A. Uncovering sex differences of rodent microglia. *J Neuroinflammation* **18**, 74 (2021).
39. Hasel, P. *et al.* Defining the molecular identity and morphology of glia limitans superficialis astrocytes in vertebrates. *Cell Rep* **44**, 115344 (2025).
40. Rothstein, J.D. *et al.* Localization of neuronal and glial glutamate transporters. *Neuron* **13**, 713-25 (1994).
41. Olsen, M.L. & Sontheimer, H. Functional implications for Kir4.1 channels in glial biology: from K+ buffering to cell differentiation. *J Neurochem* **107**, 589-601 (2008).
42. Hart, C.G. & Karimi-Abdolrezaee, S. Recent insights on astrocyte mechanisms in CNS homeostasis, pathology, and repair. *J Neurosci Res* **99**, 2427-2462 (2021).
43. Heneka, M.T., Golenbock, D.T. & Latz, E. Innate immunity in Alzheimer's disease. *Nat Immunol* **16**, 229-36 (2015).
44. Fisher, T.M. & Liddelow, S.A. Emerging roles of astrocytes as immune effectors in the central nervous system. *Trends Immunol* **45**, 824-836 (2024).
45. Rupareliya, V.P., Singh, A.A., Butt, A.M., A, H. & Kumar, H. The "molecular soldiers" of the CNS: Astrocytes, a comprehensive review on their roles and molecular signatures. *Eur J Pharmacol* **959**, 176048 (2023).
46. Colonna, M. & Butovsky, O. Microglia Function in the Central Nervous System During Health and Neurodegeneration. *Annu Rev Immunol* **35**, 441-468 (2017).

47. Nimmerjahn, A., Kirchhoff, F. & Helmchen, F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. *Science* **308**, 1314-8 (2005).
48. Jiwaji, Z. & Hardingham, G.E. Good, bad, and neglectful: Astrocyte changes in neurodegenerative disease. *Free Radic Biol Med* **182**, 93-99 (2022).
49. Lopez-Ortiz, A.O. & Eyo, U.B. Astrocytes and microglia in the coordination of CNS development and homeostasis. *J Neurochem* **168**, 3599-3614 (2024).
50. Alhadidi, Q.M. *et al.* Astrocytes in functional recovery following central nervous system injuries. *J Physiol* **602**, 3069-3096 (2024).
51. Wes, P.D., Holtman, I.R., Boddeke, E.W., Moller, T. & Eggen, B.J. Next generation transcriptomics and genomics elucidate biological complexity of microglia in health and disease. *Glia* **64**, 197-213 (2016).
52. Vezzani, A. & Viviani, B. Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. *Neuropharmacology* **96**, 70-82 (2015).
53. Verkhratsky, A., Matteoli, M., Parpura, V., Mothet, J.P. & Zorec, R. Astrocytes as secretory cells of the central nervous system: idiosyncrasies of vesicular secretion. *EMBO J* **35**, 239-57 (2016).
54. Kettenmann, H., Kirchhoff, F. & Verkhratsky, A. Microglia: new roles for the synaptic stripper. *Neuron* **77**, 10-8 (2013).
55. Heppner, F.L., Ransohoff, R.M. & Becher, B. Immune attack: the role of inflammation in Alzheimer disease. *Nat Rev Neurosci* **16**, 358-72 (2015).
56. Trainor, A.R., MacDonald, D.S. & Penney, J. Microglia: roles and genetic risk in Parkinson's disease. *Front Neurosci* **18**, 1506358 (2024).
57. Clarke, B.E. & Patani, R. The microglial component of amyotrophic lateral sclerosis. *Brain* **143**, 3526-3539 (2020).
58. Yin, Z. *et al.* APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFbeta-mediated checkpoints. *Nat Immunol* **24**, 1839-1853 (2023).
59. Bond, S., Saxena, S. & Sierra-Delgado, J.A. Microglia in ALS: Insights into Mechanisms and Therapeutic Potential. *Cells* **14**(2025).
60. Hammond, T.R. *et al.* Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes. *Immunity* **50**, 253-271 e6 (2019).
61. Gao, C., Jiang, J., Tan, Y. & Chen, S. Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. *Signal Transduct Target Ther* **8**, 359 (2023).
62. Migliarini, S. *et al.* Microglia Morphological Changes in the Motor Cortex of hSOD1(G93A) Transgenic ALS Mice. *Brain Sci* **11**(2021).
63. Mitchell, M.W., Grandizio, C., Turan, N. & Requesens, D.V. An induced pluripotent stem cell line (CIMRi001-A) from a Vici syndrome donor with a homozygous recessive c.1007A>G (p.Q336R) mutation in the EPG5 gene. *Stem Cell Res* **63**, 102833 (2022).

Figure 1. Summary of whole animal deficits in *Epg5* mutant mouse models. **A,B.** Weight comparison of mutant homozygous mutants with sibling control wild-type mice at 4 weeks (**A**) and 8 weeks of age (**B**). **C-E.** Compared with control mice (**C**), *W860X* homozygous mutant mice (**D**) display poorly placed hindlimbs when attempting to bear weight at 4 months of age. Hindlimb function in homozygous *W860X* mice progressively worsened by 7 months of age (**E**). **F-I.** Assessment of the motor function of *W860X* (**F, G**) and KO (**H, I**) mutant mice via the rotarod test. Compared with age-matched control siblings, homozygous mutant mice have a poor capacity to navigate the rotarod test of coordination. Mutant mice fail the test at a lower speed of rotation ('speed at fall'; **F, H**) and at a shorter time ('latency to fall'; **G, I**) on the apparatus. At 12 weeks of age, some homozygous mutant animals are unable to initiate the rotarod test, all *W860X* mice fail at 14 weeks, and all *KO* mice fail at 16 weeks. *wt*; homozygous wild-type, *KO*; homozygous mutant for the *KO* allele; *W860X*; homozygous mutant for the *W860X* allele. Analysis of data from wild-type and mutant mice at a given timepoint was performed via an unpaired t test.

****, $p<0.0001$; ***, $p<0.001$; **, $p<0.01$. *, $p<0.05$.


A
4 weeks
body weight, g
****
****
*
wt
KO
W860X
wt
KO
W860X
male
female


B
8 weeks
***
****
*
wt
KO
W860X
wt
KO
W860X
male
female

C

D

E


F
speed at fall
rpm
***
****
****
8 wk
10 wk
12 wk
14 wk


G
Latency to fall
seconds
***
****
****
8 wk
10 wk
12 wk
14 wk
+/+
W860X/W860X
failed to initiate test


H
speed at fall
rpm
*
**
8 wk
10 wk
12 wk
14 wk
16 wk


I
Latency to fall
seconds
*
**
8 wk
10 wk
12 wk
14 wk
16 wk
+/+
KO/KO
failed to initiate test

Figure 2. Molecular deficits in *Epg5* transcript stability and markers of autophagy in tissues derived from *Epg5* mutant mice. **A.** Assessment of *Epg5* transcript stability in control and *Epg5* mutant mice at 6 months of age via an RT–qPCR primer pair that amplifies the 3' end of the *Epg5* transcript. Unstable *Epg5* transcript in spinal cord tissue (A) from mice with mutations that recapitulate pathogenic variants. *Epg5* transcript levels in cerebellar tissues (B) were reduced but not significantly. **B,C**. Western blot analysis of the spinal cord tissue of *Epg5* mutant mice at 7 months of age was performed to detect the expression of LC3, a marker of autophagy. Note the increased accumulation of autophagosome-associated LC3-II compared to cytoplasmic LC3 (**C**). *wt*; homozygous wild-type, *KO*; homozygous mutant for the *KO* allele; *W860X*; homozygous mutant for the *W860X* allele. Analysis of gene expression levels between wild-type and mutant mice was performed via an unpaired t test. ***, $p<0.001$.


A
Epg5 transcript, 3' probe
cerebellum
spinal cord
Relative Abundance
3
2
1
0
***
wt
KO
W860X
B
KO
W860X
wt
mut
wt
mut
15 kDa
50 kDa
LC3-I
LC3-II
a-Tubulin
C
Relative Abundance
8
6
4
2
0
LC3 II
LC3 I
wt
mut
wt
mut
KO
W860X

Figure 3. Transcriptomic analysis of CNS tissues shows a range of molecular deficits associated with *Epg5* pathogenic variants. **A,B.** Volcano plot from whole tissue transcriptomic analysis of anterior spinal cord (**A**) and cerebellum (**B**) showing differentially expressed genes (DEGs) *Epg5 W860X* homozygous mutant mice compared to control age matched siblings. Select genes of interest are marked. **C.** Venn diagram of overlapping differentially expressed genes in *Epg5 W860X* mutant CNS tissues. For this analysis, genes were identified which have both 2-fold or greater up- or downregulation and adjusted P value less than 0.01 **D,E.** Gene Ontology (GO; E) and pathway analysis of overlapping CNS DEG gene signature in *Epg5 W860X* mutant mice. **F.** Heat map of differentially expressed genes from spinal cord and cerebellum of *Epg5 W860X* from transcriptomic analysis of select genes associated with a previously identified disease-associated microglia signature in other mouse neurological damage models. Genes that were absent from the transcriptomic analysis of the cerebellum (*Clec7a* and *Ccl4*) were assessed with Taqman qPCR. Note substantial number of these genes are upregulated in the CNS of *Epg5 W860X* mutant mice. **G, H.** Gene expression analysis of purified microglia from brain of 7 month old control mice or *W860X* homozygous mutant mice. Microglia were purified from whole brain via enzymatic dissociation and CD11b magnetic microbeads, then used for total RNA purification for gene expression analysis. Upregulation of disease associated microglia (**G**) and other markers associated with microglial activation (**H**) in mutant microglia compared to control mice, indicating increased expression of these genes in microglia.


A
spinal cord
-log10(padj)
log2(FC)
Myoc
C4b
Gpnmb
Mpeg1
Clec7a
Lilrb4a
Gfap
Itgax
Cst7
B
cerebellum
Gfap
C4b
Irf7
Mpeg1
Gpnmb
Myoc
Itgax
Cst7
C
spinal cord
888 total
647 unique
241 overlap
cerebellum
320 total
79 unique
D
Pathway analysis
-log(p-value)
Neutrophil degranulation
Neuroinflammation signaling pathway
Pathogen induced cytokine storm signaling pathway
Tuberculosis active signaling pathway
Pattern recognition receptors of bacteria and viruses
Interferon alpha/beta signaling
GPVI-mediated activation cascade
Complement system
Phagosome formation
Leukocyte extravasation signaling
positive z-score
z-score = 0
E
Gene Ontology - Biological Processes
-log10(padj)
Immune system process
Immune response
Defense response
Defense response to other organism
Response to biotic stimulus
Response to other organism
Response to external biotic stimulus
Response to external stimulus
Defense response to symbiont
Interspecies interactions
F
expression log2
cerebellum
spinal cord
Cst7
Lpl
Clec7a
Itgax
Apoe
Axl
Ctsd
Ctsb
Cd68
Fth1
Ftl1
Lyz2
Trem2
Cd9
Cd63
Csf1
Timp2
Spp1
Lgals3
Ccl6
B2m
Ccl3
Ccl4
Tmem119
P2ry12
P2ry13
Sall1
Siglech
Cx3cr1
G
Cst7
Clec7a
Itgax
relative expression
wt
W860X
H
Lilrb4a
Irf7
Ccl4
relative expression
wt
W860X

Figure 4. Comparison of gene expression defects between *Epg5* mutant alleles. The expression of select differentially expressed genes identified from the transcriptomic analysis of *Epg5* mutant mice was examined via qPCR via TaqMan assays. **A-D**. Comparison of gene expression deficits in the spinal cord (A, B) and cerebellum (C, D) of the three *Epg5* homozygous mutant mice and age-matched sibling wild-type control mice at 6 months of age. Compared with the wild-type controls, all the mutants presented significant deficits in gene expression of these selected markers at 6 months of age. *wt*; homozygous wild-type, *KO*; homozygous mutant for the *KO* allele; *W860X*; homozygous mutant for the *W860X* allele. Analysis of gene expression levels between wild-type and mutant mice via one-way ANOVA. ****, $p<0.0001$; ***, $p<0.001$; **, $p<0.01$; *, $p<0.05$.


A
spinal cord
relative expression
Gfap
Gpnmb
Tlr7
Cst7
Itgax
Myoc
WT
KO
W865X
B
spinal cord
expression log2
KO
W865X
Gfap
C4b
Gpnmb
Itgax
Cst7
Lilrb4
Mpeg1
Tlr7
Tlr2
Oas2
Irf7
Myoc
Epg5
C
cerebellum
relative expression
Gfap
Gpnmb
Tlr7
Cst7
Itgax
C4b
WT
KO
W860X
D
cerebellum
expression log2
KO
W865X
Gfap
C4b
Gpnmb
Itgax
Cst7
Lilrb4
Mpeg1
Tlr7
Tlr2
Oas2
Irf7
Myoc
Epg5

Figure 5. Comparison of gene expression defects between *Epg5* mutant alleles and effects on age. Age effects on gene expression deficits in *Epg5 W860X* (**A, B**) and *Epg5 KO* (**C, D**) CNS tissues. Tissues from the anterior spinal cord (**A, C**) and cerebellum (**B, D**) were isolated from the indicated mutants between 2 months and 6 months of age for gene expression analysis. Relative expression is based on comparisons with wild-type mice at the 2-month timepoint. *wt*; homozygous wild-type, *KO*; homozygous mutant for the *KO* allele; *W860X*; homozygous mutant for the *W860X* allele. Analysis of gene expression levels between wild-type and mutant mice in a given cohort via one-way ANOVA. ****, $p<0.0001$; ***, $p<0.001$; **, $p<0.01$; *, $p<0.05$.


A spinal cord
Epg5 W860X
Gfap
Gpnmb
Itgax
relative expression
wt W860X wt W860X
2 mo 6 mo
C spinal cord
Epg5 KO
wt KO wt KO
B cerebellum
Tnc
D cerebellum

Figure 6. Glial expansion in the spinal cord of *Epg5* mutant mice. Anterior spinal cord tissues, corresponding to the region around cervical vertebra 6 C6, were collected from 7-month-old control (**A, C, F, I, L**) or *Epg5 W860X* homozygous mutant mice (**B, D, G, J, M**) for histological analysis. **A-B.** Histochemical analysis to detect GFAP in the ventral spinal cord. A substantial increase in GFAP-positive cells was observed throughout the spinal cord in the *Epg5 W860X* homozygous mutant mice. Scale bar, 100 μm. **C–N**. Immunofluorescence was used to detect astrocytes (GFAP; green), microglia (IBA-1; red), and nuclei (DAPI; blue) in the spinal cord. **C,D.** Expanded microglia and astrocytes were observed throughout the spinal cord in the *Epg5 W860X* homozygous mutant mice. Scale bar, 300 μm. **E–N**. High-magnification assessment of microglia and astrocytes in specific regions of the spinal cord (**E**; diagram generated with Biorender). **F,G.** High-magnification image of the ventral gray matter of the spinal cord showing expanded astrocytes and microglia, with microglia demonstrating morphological changes, including thickened and more extensive processes and a large size, suggesting an activated phenotype (arrowheads). Scale bar, 100 μm. **H.** Quantification of the increase in microglia in the ventral horn gray matter of the spinal cord as a percentage of the total image area, demonstrating a quantitative increase in microglial content. **I,J.** Region of the dorsal funiculus of the spinal cord. Scale bar, 150 μm. **K.** Substantial expansion of microglia in the dorsalmost region of the dorsal funiculus. **L,M.** Details of the ventral border of the spinal cord. The top region of each image shows microglia, which are substantially increased in this region. The bottom portion of each image shows astrocytes, including the *glia limitans superficialis*, which are substantially expanded in the border region of the spinal cord. Scale bar, 100 μm. **N.** Quantification of astrocyte content in the ventral spinal cord and ventral border. Analysis of cell quantification between wild-type and mutant mice was performed via an unpaired t test. ****, $p<0.0001$.


A
B
E
K
I,J
F-H
L-N
IBA-1
GFAP
DAPI
F
G
H
microglia
ventral grey matter
Area of fluorescence/ total image area
****
wt
W860X
C
D
I
J
K
microglia
dorsal funiculus
Area of fluorescence/ total image area
wt
W860X
L
M
N
astrocytes
ventral white matter
Area of fluorescence/ total image area
****
wt
W860X

Figure 7. Glial expansion in the brain and cerebellum of *Epg5* mutant mice. Whole brains were collected from 7-month-old *Epg5W860X* homozygous mutant mice for histological analysis. **A-D.** Histochemical analysis to detect GFAP, a marker of astrocytes in the brain (**A, B;** scale bar, 1 mm), and focus on the cerebellum (**C, D**) in control (**A, C**) or *Epg5 W860X* homozygous mutant mice (**B, D**). A substantial increase in GFAP-positive cells was observed throughout all regions of the brain, including the cerebellum. **E-G**. Immunofluorescence was used to detect astrocytes (GFAP; green), microglia (IBA-1; red), and nuclei (DAPI; blue) in the indicated regions of the cerebellum (E; diagram generated with Biorender) in control (**F**) or *Epg5 W860X* homozygous mutant mice (**G**). Expanded microglia and astrocytes are observed in all layers of the cerebellum of *Epg5W860X* homozygous mutant mice. Scale bar, 200 μm. Layers of the cerebellum are indicated. ML, molecular layer; PCL, Purkinje cell layer; IGL, internal granule layer; WM, white matter.


A
B
C
D
E
F,G
IBA-1
GFAP
DAPI
F
ML
PCL
IGL
WM
IGL
PCL
ML
G
ML
PCL
IGL
WM
IGL
PCL
ML

Supplemental Figure 1. Longitudinal weight data of *Epg5* mutant mice. Mice were weighed weekly to monitor weight and for monitoring animal welfare. **A, B.** Weight data for control wildtype littermates or homozygous mutant *W860X* males (**A**) or females (**B**). **C,D.** Weight data for control wildtype littermates or homozygous mutant *KO* males (**C**) or females (**D**).

Supplemental Figure 1



Supplemental Figure 2. Uncropped western image. Full blot of lanes presented in Figure 2B. Middle portion of the blot was removed to eliminate samples not presented in this study.

Supplemental Figure 2



Supplemental Figure 3. Additional gene expression analysis of spinal cord tissues from *W860X* and *KO* homozygous mutant mice compared to wildtype control sibling mice.

Supplemental Figure 3



Supplemental Figure 4. Additional gene expression analysis of cerebellum tissues from *W860X* and *KO* homozygous mutant mice compared to wildtype control sibling mice.

Supplemental Figure 4



Supplemental Figure 5. Additional gene expression analysis of spinal cord and cerebellum tissues at 2 months and 6 months of age from *W860X* and *KO* homozygous mutant mice compared to wildtype control sibling mice.

Supplemental Figure 5



Supplemental Movie 1. Ataxic locomotion associated with *Epg5 W860X* homozygous mutant mice. W860X homozygous mutant male ('Mutant) or wildtype control littermate ('Wildtype') at 7 months of age were monitored in their home cage for capacity to walk and navigate cage. Note ataxic movement in W860X homozygous mutant mouse.

Supplemental video 1 screen capture

Supplemental Table 1. Summary of *Epg5* mutant alleles

Mouse allele	MGI allele nomenclature	mutation	Epg5 exon	crRNA target sequence	Donor DNA sequence	Forward Primer	Reverse Primer	Final allele sequence
KO	em1Vvn	p.R41QfsTer8	2	CGGGCTCTCCTGCTCGCGAC	n/a	AACTCCTCATGCTGAAACCACT	CCTCTCCCCTTTCTTTTAGGTCC	AACTCCTCATGCTGAAACCACTAGCTCTTTTATATCTCCTGCCTTGCTTGTAGGAAAGAAGAAGCATGAAGCCCTTCAGACTTGTGATGCAGGTCCCCTGCCAGAGACCTGTCAGCTTCTGAACTCAAAGGAGATGACCTGAAGTCGTCTGCTGACCCCCAGCTCCACAGTGATGTGTGTGGATGGAATGAAAGTGAGATGTTTGATATACCACTCACCTCCTTGACTATAGGGGATGAAGGTCCCCCGGTACAGGACACAGAGGACCTAAAAGAAAGGGGAGAGG
W860X	em2Vvn	W860X	14	CCCGAATCACAGCTATCTCT	ATAATGTTCTTGTCTTAAATTTAATTATTATTGTTTTCTTTTTAAAAAGGTTTCTTTATACTTGTTTAAAGAACTGCCTTTGTATCTTTGAAGAATTCCGACCTTCTGCCCTAGAGATAGCTGTGATTCGGGACTGGTTATTGAATAATAATCTGACAGCAGTGAAGAACAAGTTGGCCT	CATCTTTTCCAAGGAAATTCTGCAA	AGGCTCCTACTTCTCGGAAATG	CATCTTTTCCAAGGAAATTCTGCAAGAGTTTAATAATGTTCTTGTCTTAAATTTAATTATTATTGTTTTCTTTTTAAAAAGGTTTCTTTATACTTGTTTAAAGAACTGCCTTTGTATCTTTGAAGAATTCCGACCTTCTGCCCTAGCTGTGATTCGGGACTGGTTATTGAATAATAATCTGACAGCAGTGAAGAACAAGTTGGCCTGTGTGATCCTAGAAGGACTGAATTGGGGATTACTGAACAGGTATGCCATTTCCGAGAAGTAGGAGCCT

mouse acces NM_001195633.2

Supplemental Table 2. ThermoFisher TaqMan Gene Expression Assays used in this study.

Gene	Assay ID
C4b	Mm00437890_m1
Cst7	Mm00438351_m1
Gapdh	Mm99999915_g1
Gfap	Mm01253033_m1
Gpnmb	Mm01328587_m1
Irf7	Mm00516788_m1
Itgax	Mm00498701_m1
Lilrb4a	Mm01614371_m1
Epg5	Mm01257763_m1
Mpeg1	Mm01222137_g1
Myoc	Mm00447900_m1
Nkx2-9	Mm00435145_m1
Oas2	Mm00460961_m1
Tlr2	Mm00442346_m1
Tlr7	Mm00446590_m1

Supplemental Table 3. Overlapping differentially expressed genes between spinal cord and cereb

		Spinal cord		Cerebellum		
		Log2 (FC)	padj	Log2 (FC)	padj	
9930111J21R	9930111J21R	1.09323696	6.98E-16	1.33038402	0.00322291	
Abcc3	Abcc3	2.12550858	1.73E-07	1.56327374	0.00217837	
Adgre1	Adgre1	3.08041469	5.13E-165	2.33614275	2.62E-26	
Apobec1	Apobec1	2.43876645	2.34E-63	1.4175323	1.27E-06	
Arhgap25	Arhgap25	1.75621845	7.46E-22	1.32557032	0.00448986	
Arhgap30	Arhgap30	1.56735543	9.94E-58	1.41747037	0.00015443	
Arhgap45	Arhgap45	1.31513497	5.85E-43	1.04870243	1.24E-07	
Aspg	Aspg	2.72973722	3.93E-158	1.70045847	1.19E-20	
Atf3	Atf3	2.70013561	1.17E-30	1.02539951	0.00363607	
B2m	B2m	1.99016329	1.24E-134	2.13836775	1.95E-152	
B430306N03	B430306N03	3.26968387	1.11E-26	4.50528311	6.23E-08	
Blnk	Blnk	1.56527998	1.92E-28	1.66418325	5.93E-05	
Bst2	Bst2	2.32672814	4.18E-50	3.03118447	4.73E-55	
C1qa	C1qa	2.83889106	1.02E-181	2.42318726	5.95E-140	
C1qb	C1qb	2.4770435	3.95E-130	1.98774015	7.96E-73	
C1qc	C1qc	2.48082661	6.62E-158	2.03478932	2.60E-86	
C1ra	C1ra	3.11896874	3.44E-62	1.24464176	0.0079316	
C3	C3	2.97293034	1.85E-226	3.6966202	1.87E-67	
C3ar1	C3ar1	2.77905432	1.79E-99	2.49205263	4.79E-20	
C4b	C4b	3.24945218	0	4.097653	0	
Capn11	Capn11	-1.6181141	1.95E-05	-1.8847395	3.56E-06	*
Casp12	Casp12	2.06220661	3.80E-90	1.10847482	1.82E-07	
Casp4	Casp4	1.12751752	5.53E-07	2.39660891	0.00043959	
Ccl12	Ccl12	3.36680058	1.67E-09	3.76551008	0.00014058	
Ccl3	Ccl3	3.96950057	1.91E-29	3.51187528	2.67E-05	
Ccl5	Ccl5	1.99112676	0.00042323	3.45421804	6.25E-05	
Cd109	Cd109	2.233577	2.89E-81	1.56588797	1.52E-07	
Cd180	Cd180	1.745439	3.00E-19	2.11347131	1.90E-13	
Cd22	Cd22	2.453873	1.62E-05	3.74602405	2.95E-13	
Cd300c2	Cd300c2	2.10913094	4.18E-50	1.98900905	2.17E-08	
Cd300lf	Cd300lf	1.42525364	8.90E-19	2.20563695	0.00023274	
Cd33	Cd33	1.40523312	5.06E-15	1.50917871	5.72E-10	
Cd37	Cd37	1.39699777	7.46E-16	1.3810384	9.34E-08	
Cd4	Cd4	2.36723969	4.51E-05	2.36629778	0.00365418	
Cd44	Cd44	1.62018019	8.61E-54	1.11814697	1.45E-22	
Cd48	Cd48	3.81773186	7.06E-87	2.48453573	3.16E-07	
Cd52	Cd52	3.18278585	9.67E-80	2.23261055	2.65E-07	
Cd53	Cd53	1.64481494	1.52E-51	1.4575883	5.46E-08	
Cd68	Cd68	3.3192545	8.49E-293	2.30429753	9.08E-61	
Cd84	Cd84	2.07652747	3.81E-143	2.55015394	1.13E-22	

Cd86	Cd86	1.29260542	1.09E-10	1.69325869	0.00075391
Cebpd	Cebpd	3.04244063	1.24E-110	1.3648677	1.33E-07
Cp	Cp	2.3877424	4.68E-209	1.01235372	1.34E-21
Csf2rb	Csf2rb	2.23505878	1.63E-34	2.00183887	9.18E-06
Csf3r	Csf3r	1.77824849	1.91E-47	1.78261377	8.94E-18
Cst7	Cst7	7.08358303	1.27E-73	5.59410643	2.30E-13
Ctsh	Ctsh	1.66905581	2.22E-18	1.04331553	1.96E-12
Ctss	Ctss	2.04824464	1.34E-99	2.03825339	1.25E-99
Cxcl10	Cxcl10	3.20387296	6.57E-07	4.49244054	3.57E-26
Cxcl16	Cxcl16	2.4554051	7.76E-27	1.5013931	1.33E-07
Cxcl5	Cxcl5	1.95920013	2.92E-15	2.81624929	3.48E-06
Cxcr4	Cxcr4	1.7517299	1.19E-42	1.71181145	1.42E-06
Cyba	Cyba	2.55570313	3.96E-93	1.21737819	1.63E-06
Cybb	Cybb	3.31367843	1.11E-185	2.58867483	9.72E-15
Cybrd1	Cybrd1	1.07973224	2.89E-16	1.63721629	8.61E-13
Cyp1b1	Cyp1b1	1.3389824	3.25E-27	1.05310163	9.07E-05
Cyth4	Cyth4	1.17195832	1.11E-23	1.32300354	1.78E-10
Ddx60	Ddx60	2.130275	1.54E-28	3.99673794	9.12E-49
Dock2	Dock2	1.89784946	3.35E-11	1.57202733	2.57E-07
Dram1	Dram1	1.06683997	0.00036719	1.35714395	0.0081225
Elf4	Elf4	1.93386756	6.40E-19	1.41327999	6.53E-05
Emp3	Emp3	1.79141591	0.00077939	1.22367421	0.00075711
Endou	Endou	1.87109118	1.98E-31	1.92810235	6.80E-08
Epsti1	Epsti1	1.95196933	1.74E-12	2.81745101	4.02E-06
Fcer1g	Fcer1g	2.57228129	9.12E-20	2.14359677	4.88E-23
Fcgr2b	Fcgr2b	3.38787	2.57E-210	2.74587265	1.89E-34
Fcgr3	Fcgr3	1.656828	3.43E-53	1.45545798	1.96E-13
Fcrls	Fcrls	2.9554464	8.90E-256	2.21805027	1.39E-42
Fermt3	Fermt3	1.41069548	2.83E-24	1.28014374	4.38E-06
Fgr	Fgr	3.2053797	3.17E-53	2.65315916	0.00585116
Flnc	Flnc	1.56141239	1.81E-99	1.24577877	2.69E-19
Ftl1	Ftl1	1.8844304	9.92E-185	1.01330848	5.80E-75
Fyb	Fyb	2.17330256	1.02E-63	1.82447571	4.27E-12
Gbp10	Gbp10	3.96787969	3.50E-05	4.44224147	3.47E-30
Gbp2	Gbp2	2.03551463	2.58E-77	1.98818105	8.70E-40
Gbp3	Gbp3	1.59621172	1.35E-41	2.68173003	2.94E-74
Gbp5	Gbp5	1.60396385	1.75E-31	1.64147129	1.04E-15
Gbp6	Gbp6	2.53213722	6.28E-119	3.88841536	2.62E-89
Gbp7	Gbp7	1.13764387	1.23E-20	2.15340475	4.09E-39
Gbp9	Gbp9	1.2293972	2.92E-13	1.75609935	3.68E-30
Gfap	Gfap	1.859965	2.41E-187	2.42280036	0
Gm4951	Gm4951	1.62456055	3.88E-12	4.42584264	2.69E-20
Gna15	Gna15	1.11235084	3.95E-05	1.17244283	0.00265629

Gpnmb	Gpnmb	6.96937547	0	3.11687788	2.36E-107
Gpsm3	Gpsm3	1.31165269	4.37E-06	1.09670299	0.00227162
Gpx3	Gpx3	1.751674	1.79E-44	2.11788307	1.07E-05
Gsdmd	Gsdmd	1.08427717	3.99E-10	1.07954077	1.92E-05
H2-K1	H2-K1	1.53826538	4.01E-43	1.87352754	4.21E-12
H2-Q4	H2-Q4	1.17785503	3.74E-27	2.23186312	1.13E-08
H2-Q6	H2-Q6	1.35268617	6.68E-41	3.32350483	1.51E-05
H2-Q7	H2-Q7	1.43095142	1.40E-23	2.65803239	7.67E-13
H2-T23	H2-T23	1.17789121	5.25E-17	1.9377008	1.70E-51
Hacd4	Hacd4	2.48283111	3.56E-78	1.05527605	0.00017758
Havcr2	Havcr2	1.43021189	3.17E-23	1.55293502	0.00011274
Hck	Hck	1.63157853	9.90E-30	1.89681402	6.73E-06
Hcls1	Hcls1	1.72310648	8.01E-20	1.21891204	6.07E-10
Herc6	Herc6	1.17841776	6.75E-18	2.04998062	2.02E-21
Hmox1	Hmox1	2.0949206	4.74E-101	1.15696662	9.42E-07
Hpgds	Hpgds	1.10793338	1.30E-32	1.35408527	2.63E-10
Hpse	Hpse	4.04279887	2.57E-119	3.89997715	2.63E-17
Hvcn1	Hvcn1	2.87627013	9.57E-97	2.2310342	5.67E-16
Icam1	Icam1	2.33021974	4.98E-100	1.53898644	1.62E-11
Ifi204	Ifi204	1.74784008	1.44E-16	4.26484537	1.32E-25
Ifi206	Ifi206	3.76255694	4.23E-06	6.37423246	5.88E-16
Ifi207	Ifi207	4.75417028	1.07E-32	4.31043902	6.63E-25
Ifi209	Ifi209	2.15622861	1.10E-12	3.83016174	1.08E-07
Ifi211	Ifi211	3.25123308	3.75E-11	5.54861776	1.40E-05
Ifi213	Ifi213	1.20489433	1.03E-06	4.60156466	1.35E-24
Ifi27l2a	Ifi27l2a	3.09415307	8.32E-33	4.5272449	4.88E-12
Ifi35	Ifi35	1.01853263	1.28E-11	1.78594362	2.75E-10
Ifi44	Ifi44	2.1088134	2.13E-20	3.43396532	1.41E-33
Ifi47	Ifi47	1.71500301	7.11E-11	2.71436936	1.40E-10
Ifih1	Ifih1	1.15167678	7.44E-15	1.98325284	4.53E-48
Ifit1	Ifit1	1.80210266	9.03E-36	4.33450463	7.10E-221
Ifit3	Ifit3	1.58082475	3.87E-12	3.43150581	3.34E-60
Ifit3b	Ifit3b	1.52220083	4.06E-38	3.29314397	7.43E-147
Ifitm3	Ifitm3	1.82946232	4.97E-70	2.43416081	6.56E-56
Igsf6	Igsf6	2.52037471	1.25E-32	2.07354986	0.00037128
Igtp	Igtp	1.00030597	2.69E-15	2.89889032	1.23E-62
Iigp1	Iigp1	1.24035482	6.42E-13	2.34398713	3.97E-24
Ikzf1	Ikzf1	1.3934617	8.33E-18	1.29298109	5.95E-06
Inpp5d	Inpp5d	1.27190344	6.54E-29	1.24737539	2.20E-10
Irf5	Irf5	1.21467096	1.59E-09	1.45034757	3.46E-06
Irf7	Irf7	1.79885208	3.39E-14	4.27563941	1.19E-189
Irf8	Irf8	1.75961838	1.86E-43	1.469239	5.83E-10
Irf9	Irf9	1.41117651	1.74E-42	2.19934043	1.40E-127

Irgm1	Irgm1	1.29359346	1.36E-42	2.84748724	7.70E-135	
Irgm2	Irgm2	1.40746868	7.76E-31	2.35813783	4.33E-12	
Isg15	Isg15	1.97567196	5.42E-11	3.53013719	2.10E-37	
Itgam	Itgam	1.39487586	1.08E-50	1.4785927	0.00015012	
Itgax	Itgax	4.86246051	1.09E-90	2.94781726	2.42E-07	
Itgb2	Itgb2	2.65340641	2.09E-134	2.12792947	6.59E-25	
Kcns1	Kcns1	1.82837515	3.09E-56	1.193473	5.00E-06	
Laptm5	Laptm5	1.71192945	2.20E-115	1.55676397	3.90E-41	
Lcn2	Lcn2	8.23824511	6.01E-175	6.98157203	9.14E-17	
Lcp2	Lcp2	1.15918121	8.83E-08	1.57088278	1.98E-05	
Lgals3	Lgals3	3.21109024	6.56E-05	2.6015204	9.07E-32	
Lgals3bp	Lgals3bp	2.58888466	4.35E-115	3.20785225	7.22E-23	
Lgals9	Lgals9	1.23594525	4.94E-12	2.31785955	2.22E-61	
Lilrb4a	Lilrb4a	6.11679115	1.24E-207	3.64229431	2.99E-10	
Ly86	Ly86	1.31532624	6.32E-28	1.28221394	1.69E-07	
Ly9	Ly9	6.23861607	1.88E-116	4.55341404	2.71E-23	
Lyz2	Lyz2	5.91046957	0	2.76446151	6.99E-121	
Mafb	Mafb	1.22837804	1.23E-34	1.19402998	5.03E-11	
Met	Met	1.51339207	1.19E-21	1.81739235	0.00015166	
Mmp19	Mmp19	2.39631242	9.66E-56	1.14488893	0.00961152	
Mmrn2	Mmrn2	1.07996509	1.31E-08	1.16303462	8.17E-12	
Mndal	Mndal	1.18258563	6.07E-07	2.01059136	2.11E-14	
Mpeg1	Mpeg1	3.24940321	1.39E-278	2.6585749	2.95E-163	
Ms4a6b	Ms4a6b	2.29815961	7.68E-19	2.64518093	1.96E-06	
Ms4a6c	Ms4a6c	4.30058984	6.35E-89	2.67681065	9.55E-06	
Ms4a6d	Ms4a6d	3.04188719	9.87E-61	2.78686839	4.98E-08	
Ms4a7	Ms4a7	3.53125441	9.59E-82	2.87197894	0.00019914	
Myo1f	Myo1f	2.57091034	2.31E-80	1.86017073	3.91E-15	
Naip2	Naip2	1.72924888	4.53E-44	2.0926213	1.45E-06	
Naip5	Naip5	1.63477516	6.45E-25	1.44817403	0.00402905	
Ncf1	Ncf1	1.80737296	1.29E-63	1.56973261	7.66E-11	
Nckap1l	Nckap1l	1.50529251	3.41E-59	1.39158974	4.56E-09	
Nfam1	Nfam1	1.580226	1.67E-31	1.24620575	0.00304052	
Nkx2-9	Nkx2-9	-1.7853189	6.56E-24	-1.5363872	0.0012498	*
Nlrc5	Nlrc5	2.25657049	3.13E-28	3.02177144	1.84E-08	
Oas1a	Oas1a	2.55551833	8.45E-23	3.89118159	2.50E-32	
Oas1g	Oas1g	3.42955597	1.06E-18	4.80820977	1.60E-17	
Oas2	Oas2	3.18867506	2.22E-26	4.02275279	2.65E-20	
Oasl1	Oasl1	1.33293957	0.00199826	3.64436117	3.60E-23	
Oasl2	Oasl2	1.59728013	8.59E-15	4.5741957	0	
Osgin1	Osgin1	3.00950338	2.73E-18	1.597678	0.00047451	
Osmr	Osmr	2.60423198	4.54E-106	1.29034216	8.51E-14	
P2ry6	P2ry6	1.60154361	3.59E-15	1.28417266	0.00361603	

Parp10	Parp10	1.15464847	1.49E-13	1.75256971	3.62E-14
Parp14	Parp14	1.62123279	6.98E-33	2.7252473	2.93E-94
Phf11b	Phf11b	1.43054	0.00062	3.52445404	2.60E-06
Phf11d	Phf11d	1.301265	4.97E-07	3.07515079	8.32E-12
Pik3ap1	Pik3ap1	1.75375416	4.19E-62	1.61840688	2.94E-10
Pik3cg	Pik3cg	1.41647866	5.57E-35	1.5509373	1.51E-07
Pik3r5	Pik3r5	1.34886588	7.37E-24	1.47278377	0.00056886
Pirb	Pirb	3.47346512	1.90E-77	3.17641247	7.93E-11
Pla2g5	Pla2g5	1.0454165	2.22E-09	1.5300915	1.75E-08
Plau	Plau	2.44026133	1.07E-53	1.38022124	0.00867992
Plaur	Plaur	2.46744804	1.08E-17	1.31527775	0.00258336
Plcg2	Plcg2	1.56947193	2.78E-72	1.08154153	2.09E-06
Pld4	Pld4	1.2023639	4.28E-15	1.21704964	1.15E-07
Plscr2	Plscr2	1.34768233	4.24E-22	1.09168062	1.70E-05
Psmb8	Psmb8	2.21546109	2.41E-09	2.12590838	1.46E-21
Psmb9	Psmb9	1.37956227	7.48E-09	2.09133326	3.24E-10
Ptafr	Ptafr	1.86952626	8.90E-28	2.52990537	3.34E-07
Ptgs2	Ptgs2	1.77551623	4.95E-14	2.09768419	0.00051199
Ptpn6	Ptpn6	1.90240483	4.78E-16	1.89198975	1.44E-18
Ptprc	Ptprc	1.66898916	5.19E-67	1.98218167	3.05E-12
Pycard	Pycard	1.67769381	9.20E-25	1.24016306	0.00014135
Qprt	Qprt	1.07912428	0.0003234	1.06267953	0.0026013
Rac2	Rac2	1.25024663	7.28E-12	1.39076245	0.00047451
Rasal3	Rasal3	1.38812073	4.09E-11	1.15441901	0.00133359
Rnf213	Rnf213	1.02936303	4.53E-44	2.92297347	1.60E-269
Rsad2	Rsad2	2.39190388	8.86E-67	4.05477845	1.16E-111
Rtp4	Rtp4	1.33458926	6.19E-22	4.02740414	1.78E-81
S1pr3	S1pr3	2.15344914	4.62E-95	1.06766959	2.29E-07
Samsn1	Samsn1	1.888985	6.79E-22	1.54356173	0.00908748
Sash3	Sash3	1.6070489	2.65E-16	1.2284922	0.00995937
Sctr	Sctr	2.03428616	2.22E-18	2.18036048	0.00979115
Serpina3n	Serpina3n	4.31870614	0	2.69367338	4.53E-62
Siglec1	Siglec1	4.15375252	1.88E-116	3.07308979	4.05E-20
Slamf9	Slamf9	2.381156	6.04E-33	1.56869667	0.00839036
Slc11a1	Slc11a1	3.338065	6.41E-25	2.25945412	1.75E-20
Slc15a3	Slc15a3	2.202387	2.80E-39	1.03871766	0.00248646
Slc43a3	Slc43a3	3.391145	1.20E-78	2.20339326	4.14E-11
Slfn2	Slfn2	2.44927594	2.69E-37	2.30845658	4.57E-07
Slfn5	Slfn5	1.22815019	4.24E-23	1.34205719	5.41E-39
Slfn8	Slfn8	1.81435195	1.09E-19	3.45993299	1.17E-31
Sp100	Sp100	1.21268615	4.56E-17	1.69431912	1.39E-36
Sp110	Sp110	1.26909943	4.11E-13	1.89702199	3.59E-10
Sp140	Sp140	2.31027467	1.84E-10	1.85005001	0.00063355

Spi1	Spi1	1.64679025	1.61E-07	1.30648573	3.36E-06
Stab1	Stab1	1.412411	1.78E-13	1.13929771	6.53E-19
Syk	Syk	1.70671096	3.47E-42	1.61450849	7.14E-10
Tap1	Tap1	1.04311893	2.30E-09	1.90580866	7.45E-23
Tent5c	Tent5c	1.90704566	3.33E-61	1.09685559	0.00014035
Tgtp1	Tgtp1	1.14313856	0.00238102	2.27638666	9.39E-07
Themis2	Themis2	1.947071	2.96E-25	1.88186106	1.23E-06
Timp1	Timp1	6.72298999	9.38E-96	2.13374215	0.00279707
Tlr13	Tlr13	2.32753293	2.72E-91	1.91674908	1.42E-06
Tlr2	Tlr2	2.58309712	4.29E-120	2.25703879	2.65E-14
Tlr7	Tlr7	2.23676878	2.73E-31	2.12004101	2.58E-11
Tmem106a	Tmem106a	1.84723862	2.65E-15	1.83369932	0.00023074
Tmem140	Tmem140	1.09860098	4.14E-08	1.40385403	9.85E-06
Tmem176a	Tmem176a	2.23273212	5.05E-27	1.29958885	1.91E-11
Tnfrsf1b	Tnfrsf1b	1.36348076	0.00263848	1.70122722	1.29E-11
Trem2	Trem2	2.58713712	8.40E-195	2.18780217	2.09E-44
Treml2	Treml2	2.42613098	2.81E-22	3.41506429	6.92E-07
Trim12c	Trim12c	1.058529	3.19E-17	1.71640508	7.22E-15
Trim30a	Trim30a	1.81813707	9.97E-35	3.16077017	2.39E-72
Tubb6	Tubb6	1.25448578	8.35E-16	1.140325	0.00350475
Tyrobp	Tyrobp	2.75002265	8.32E-96	1.84897965	8.43E-34
Uba7	Uba7	1.08654111	9.84E-19	1.98942687	6.54E-31
Unc93b1	Unc93b1	1.28069625	1.58E-28	1.29184662	1.94E-21
Usp18	Usp18	2.26246116	9.81E-20	4.36206577	1.25E-99
Vav1	Vav1	1.78895641	8.18E-26	1.2688305	6.99E-05
Wdfy4	Wdfy4	1.22520348	4.49E-06	1.53619436	0.00016596
Xdh	Xdh	1.71104141	4.05E-39	1.21164822	3.28E-25
Zbp1	Zbp1	4.02148415	1.45E-19	4.63812852	5.92E-34
Zc3hav1	Zc3hav1	1.00055704	1.01E-36	2.02025225	3.05E-75